CN-121971430-A - Application of red clover or pharmaceutically acceptable salt or solvate thereof in preparation of drugs for preventing, delaying and/or treating heart aging and/or myocardial injury

Abstract

The invention discloses application of red clover or pharmaceutically acceptable salt or solvate thereof in preparing a medicament for preventing, delaying and/or treating heart aging and/or myocardial injury. The invention provides a new strategy and candidate substances for developing medicines, health products or functional foods for preventing, delaying and/or treating heart aging and/or myocardial injury, maintaining heart health and reducing the risks of aging-related cardiovascular diseases.

Inventors

• Ai Xiaoni
• TU PENGFEI
• GUO JINWEN
• YANG SHUIYUAN
• XIAO RONGRONG
• ZHOU YU

Assignees

• 北京大学
• 北京大橡科技有限公司

Dates

Publication Date

20260505

Application Date

20260304

Claims (10)

1. 1. The application of the red clover having the structure shown in the formula (1) or pharmaceutically acceptable salts or solvates thereof in preparing medicaments for preventing, delaying and/or treating heart aging and/or myocardial injury, (1)。
2. 2. The use according to claim 1, wherein the medicament forms a pharmaceutical formulation for preventing, delaying and/or treating heart aging and/or myocardial damage, the pharmaceutical formulation comprising praziquantel or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable adjuvant.
3. 3. The use according to claim 2, wherein the single active ingredient is praline or a pharmaceutically acceptable salt or solvate thereof, the dosage form of the medicament is an oral preparation, and the dosage of praline in the pharmaceutical preparation is 1.5-2.5 mg/kg.
4. 4. The use according to claim 1, wherein the medicament forms a pharmaceutical formulation for reducing the expression level of β -galactosidase in senescent cardiomyocytes.
5. 5. The use according to claim 1, wherein the medicament forms a pharmaceutical formulation for ameliorating weight loss caused by heart aging.
6. 6. The use according to claim 1, wherein the medicament forms a pharmaceutical formulation for improving diastolic dysfunction.
7. 7. The use according to claim 1, wherein the medicament forms a pharmaceutical formulation for reducing the expression level of the DNA damage marker γ -H2AX in aged heart tissue.
8. 8. The use according to claim 1, wherein the medicament forms a pharmaceutical formulation for reducing myocardial tissue fiber rupture and alignment disorders.
9. 9. The use according to claim 1, wherein the medicament forms a pharmaceutical formulation for reducing collagen deposition in heart tissue.
10. 10. The use according to any one of claims 1 to 9, wherein the myocardial damage is caused by one or more of coronary heart disease, myocardial hypertrophy, heart failure, angina pectoris, arrhythmia, pulmonary heart disease, myocardial infarction, myocardial ischemia reperfusion, chemotherapeutic drugs, bacteria and viruses.

Description

Application of red clover or pharmaceutically acceptable salt or solvate thereof in preparation of drugs for preventing, delaying and/or treating heart aging and/or myocardial injury Technical Field The invention relates to application of red clover or pharmaceutically acceptable salt or solvate thereof in preparing a medicament for preventing, delaying and/or treating heart aging and/or myocardial injury. Background With the increasing aging degree of the population, the disease burden related to aging has become a major health and social problem facing China and even the world. The degenerative change of the heart structure and function along with aging is the most important risk factor for causing cardiovascular diseases, the occurrence of the cardiovascular diseases can further accelerate the aging of the heart, the heart degenerative disease can be found early, and the early warning, the prevention and the treatment of the cardiovascular diseases are of great significance for realizing healthy aging. At present, although drugs such as metformin, rapamycin, NAD+ precursors (e.g. NMN/NR), senescent cell scavengers (e.g. dasatinib+quercetin) and the like have demonstrated potential in studies of delaying heart aging through lifestyle interventions such as caloric restriction, regular exercise and the like, these strategies all have significant limitations and challenges. For example, long-term use of rapamycin may cause serious side effects such as immunosuppression and metabolic disorders, while the long-term safety of metformin and senescent cell scavengers is still largely verified in non-indication people, and furthermore, significant effects in animal models are often difficult to replicate completely or have limited effects in human clinical trials, and individual differences are significant. Strict diet and exercise regimen compliance is poor and compliance with long-term frequent dosing (especially in the presence of side effects) is also a significant hurdle. Particularly, many natural products with anti-aging potential (such as resveratrol, quercetin and the like) generally face the inherent bottlenecks of low bioavailability, rapid in-vivo metabolism, undefined action targets, possibility of side effects or difficulty in maintaining effective concentration when an effective dose is achieved, and the practical application effect is severely restricted. Therefore, there is a need to develop an intervention means which has high safety, good bioavailability, clear action mechanism and easy long-term application, in particular a natural active ingredient which can overcome the bottleneck, so as to effectively meet the clinical requirement of delaying heart aging. The natural product monomer compound is a monomer component extracted and separated from natural products, and can have various pharmacological activities, and is a precious resource for developing new drugs. Red clover (PRATENSEIN) is a natural compound found in a variety of plants. Up to now, there is no report on the use of red clover in the preparation of a medicament for preventing, delaying and/or treating heart aging and/or myocardial damage. Disclosure of Invention In view of the above, the present invention aims to provide an application of red clover or a pharmaceutically acceptable salt or solvate thereof in preparing a medicament for preventing, delaying and/or treating heart aging and/or myocardial injury. The beta-galactosidase can reduce the expression level of beta-galactosidase in aging myocardial cells, can reduce the expression level of DNA injury markers gamma-H2 AX in aging heart tissues, can obviously improve the diastolic function index, and reduces the physiological changes of aging and myocardial injury related diseases such as heart tissue fibrosis, collagen deposition and the like. The invention adopts the following technical scheme to realize the aim. The invention provides an application of red clover with a structure shown in a formula (1) or pharmaceutically acceptable salt or solvate thereof in preparing medicaments for preventing, delaying and/or treating heart aging and/or myocardial injury, (1)。 The current research shows that the red clover has the biological activities of neuroprotection, improving learning and memory defects, resisting oxidation, resisting inflammation and the like, but no biological activity for preventing, delaying and/or treating heart aging and/or myocardial injury is reported. Flavonoid compounds similar in structure to red clover such as kaempferol, calycosin and the like have been reported to have antioxidant activity, but they have not been reported to have biological activity for preventing, delaying and/or treating heart aging and/or myocardial damage. Through a great deal of researches and experiments, the inventor discovers that the red clover has the biological activity of effectively delaying heart aging and reducing myocardial damage for the first time. Compared with caly